Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuel Mortier

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
BMC Infectious Diseases|May 11, 2019
Patients' high acceptability of a future therapeutic HIV vaccine in France: a French paradox?Svetlane Dimi, David Zucman, Olivier Chassany, et al.
AIDS (London, England)|August 12, 2008
Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimenConstance Delaugerre, Juliette Pavie, Pierre Palmer, et al.
American Journal of Infection Control|April 25, 2006
Consideration of age at admission for selective screening to identify methicillin-resistant Staphylococcus aureus carriers to control dissemination in a medical wardMatthieu Eveillard, Emmanuel Mortier, Evelyne Lancien, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 5, 2015
Impact of the Timing of Initiation of Antiretroviral Therapy During Primary HIV-1 Infection on the Decay of Cell-Associated HIV-DNAMoussa Laanani, Jade Ghosn, Asma Essat, et al.
Presse Medicale (Paris, France : 1983)|February 26, 2013
[Aging and HIV infection: 4 years follow-up of 149 HIV infected patients older than 60 years in West Paris agglomeration (COREVIH Île-de-France Ouest)]Gabriella Flexor, David Zucman, Huguette Berthé, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 29, 2018
First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2)Sophie Matheron, Diane Descamps, Sebastien Gallien, et al.
Neurology|December 29, 2019
Granulomatosis-associated myositis: High prevalence of sporadic inclusion body myositisYannick Dieudonné, Yves Allenbach, Olivier Benveniste, et al.
Antiviral Therapy|January 21, 2015
Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant womenMinh P Lê, Laurent Mandelbrot, Diane Descamps, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
BMC Infectious Diseases|May 11, 2019
Patients' high acceptability of a future therapeutic HIV vaccine in France: a French paradox?Svetlane Dimi, David Zucman, Olivier Chassany, et al.
AIDS (London, England)|August 12, 2008
Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimenConstance Delaugerre, Juliette Pavie, Pierre Palmer, et al.
American Journal of Infection Control|April 25, 2006
Consideration of age at admission for selective screening to identify methicillin-resistant Staphylococcus aureus carriers to control dissemination in a medical wardMatthieu Eveillard, Emmanuel Mortier, Evelyne Lancien, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 5, 2015
Impact of the Timing of Initiation of Antiretroviral Therapy During Primary HIV-1 Infection on the Decay of Cell-Associated HIV-DNAMoussa Laanani, Jade Ghosn, Asma Essat, et al.
Presse Medicale (Paris, France : 1983)|February 26, 2013
[Aging and HIV infection: 4 years follow-up of 149 HIV infected patients older than 60 years in West Paris agglomeration (COREVIH Île-de-France Ouest)]Gabriella Flexor, David Zucman, Huguette Berthé, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 29, 2018
First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2)Sophie Matheron, Diane Descamps, Sebastien Gallien, et al.
Neurology|December 29, 2019
Granulomatosis-associated myositis: High prevalence of sporadic inclusion body myositisYannick Dieudonné, Yves Allenbach, Olivier Benveniste, et al.
Antiviral Therapy|January 21, 2015
Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant womenMinh P Lê, Laurent Mandelbrot, Diane Descamps, et al.
Pageof 2